Graphy Publications
Inspiring Innovations & Discoveries
International Journal of Diabetes & Clinical Diagnosis Volume 3 (2016), Article ID 3:IJDCD-121, 3 pages
http://dx.doi.org/10.15344/2394-1499/2016/121
Short Communication
Effects of Combination Therapy with Liraglutide and Insulin Glargine as the Initial Treatment for Hyperglycemic Patients with Type 2 Diabetes: An Observational Study

Kotaro Kurasaki, Ikue Kigawa, Emi Sohara and Kumiko Hamano*

Department of Diabetes and Endocrinology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi, Nakahara, Kawasaki, Kanagawa 211-8510, Japan
Prof. Kumiko Hamano, Department of Diabetes and Endocrinology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi, Nakahara, Kawasaki, Kanagawa 211-8510, Japan; E-mail: k-hamano@kantoh.rofuku.go.jp
06 September 2016; 13 December 2016; 15 December 2016
Kurasaki K, Kigawa I, Sohara E, Hamano K (2016) Effects of Combination Therapy with Liraglutide and Insulin Glargine as the Initial Treatment for Hyperglycemic Patients with Type 2 Diabetes: An Observational Study. Int J Diabetes Clin Diagn 3: 121. doi: http://dx.doi.org/10.15344/2394-1499/2016/121

Abstract

Background: Hyperglycemia in type 2 diabetes causes glucotoxicity, which can be treated with intensive insulin therapy. However, this treatment can lead to weight gain and hypoglycemia. The present study investigated the efficacy and safety of combination therapy with liraglutide and insulin glargine as the initial treatment for patients with moderate or severe hyperglycemia.
Methods: Changes in clinical indexes such as glycated hemoglobin (HbA1c) and body mass index (BMI) were retrospectively investigated in 20 patients under combination therapy with liraglutide and insulin glargine and 10 patients treated with intensive insulin therapy.
Results: Combination therapy with liraglutide and insulin glargine significantly improved HbA1c and BMI at 3 months compared with baseline. However, BMI was not improved in patients treated with intensive insulin therapy. Severe hypoglycemia was not observed in the combination therapy group during the observation period, and no patients required switching because of gastrointestinal symptoms.
Conclusion: Combination therapy with liraglutide and insulin glargine demonstrated a superior glucoselowering effect, safety, and convenience without increasing body weight in poorly controlled patients with type 2 diabetes under hyperglycemic conditions. These results suggest that combination therapy could be considered an alternative to intensive insulin therapy.